Price
No data yet.
Social Signal Score
Analyst Ratings
Revenue
$730.6K+74.20%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jonathan Cohen
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Employees
- 14
- Beta
- 1.54
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -9.29
Financials
AIDX has only 8 quarterly periods on file — the charts below show the full history available.
Revenue
$730.6K+74.2%Net Income
$-1.51MEBITDA
$-1.23MFree Cash Flow
$-600.1KEPS (diluted)
$-0.26Shares Outstanding (diluted)
10.79M+126.5%Operating Expenses
$1.55MCash & Debt
$4.55MReturn of Capital
$67.5KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.05M | $-3.74M | $-0.60 |
| 2024 | $1.75M | $-5.55M | $-1.16 |
| 2023 | $1.42M | $-6.39M | $-1.34 |
| 2022 | $11.06M | $2.19M | $0.46 |
| 2021 | $9.62M | $2.07M | $0.44 |
| 2020 | $2.33M | $-2.02M | $-0.43 |
| 2019 | $288.3K | $-2.43M | $-0.51 |
| 2018 | $277.0K | $-1.46M | $-0.31 |
| 2017 | $313.2K | $-1.26M | $-0.27 |
| 2016 | $427.0K | $-2.23M | $-0.48 |
Valuation
AIDXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·4d ago·Neutral
…ld One-on-One Meetings with Institutional Investors at the Hard Rock Hotel New York GAITHERSBURG, Md., Oct. 02, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that President and Chief Executive Officer Jonathan Cohen and Chief Financial Officer Alan Bergman will participate in the Maxim Growth Summit 2026, being …
View source ↗ - Newsglobenewswire.com·41d ago·Positive
20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity CEO Jonathan Cohen to Detail the Company's Strongest Quarterly Performance Since Commercial Launch of Multi-Cancer Early Detection Testing, Key Takeaways from the Next Generation Dx Summit, and Path to Broader Commercial Adoption Webinar to Be Held Wednesday, September 2, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open GAITHERSBURG, Md.
View source ↗ - Newsglobenewswire.com·50d ago·Neutral
…n as of June 30, 2026, with All Convertible Note Debt Eliminated During the Quarter GAITHERSBURG, Md., Aug. 17, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20” or the “Company”), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, reported its financial and operational results for the second quarter ended June 30, 2026.
View source ↗
Earnings
Typical surprise -148.3% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-0.26 vs $-0.12miss
- Wed, May 20$-0.28 vs $-0.10miss
Estimates and results for AIDX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AIDX officers and directors.
No open-market trades in the recent filings. All 51 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
51 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AIDX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.